Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP934075.RABqwVd4l4Knvb5W7EFsVNZvBjmCidvdQ8aLlJmAVBnDI130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP934075.RABqwVd4l4Knvb5W7EFsVNZvBjmCidvdQ8aLlJmAVBnDI130_provenance.
• NP264156.RArLMg72U_hZ2FfJNvCe1dsbhB-XgJDkUmpiUYx_LVP54130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP264156.RArLMg72U_hZ2FfJNvCe1dsbhB-XgJDkUmpiUYx_LVP54130_provenance.
• NP609087.RAsvNLY0wLM05Yd5ijRYFZA7dYa6UEpiaWDrETR2rVYxc130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP609087.RAsvNLY0wLM05Yd5ijRYFZA7dYa6UEpiaWDrETR2rVYxc130_provenance.
• NP817296.RA8tmS4aAebR9Oj2OELvyGSfv2HmOfLiheZjnzqO-RSng130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817296.RA8tmS4aAebR9Oj2OELvyGSfv2HmOfLiheZjnzqO-RSng130_provenance.
• assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1296602.RAA29_W4mI0qS-3riv68x5-WzQCm-Xu7UPDJL-ZdiLp94130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1296602.RAA29_W4mI0qS-3riv68x5-WzQCm-Xu7UPDJL-ZdiLp94130_provenance.
• NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_provenance.
• NP477122.RAomNnwwTkD4o0aouebmQZZC5GdQqFeQ9nxcq1TL6HXxI130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP477122.RAomNnwwTkD4o0aouebmQZZC5GdQqFeQ9nxcq1TL6HXxI130_provenance.
• NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_provenance.
• NP477376.RA8UgOCxeQqHmN7v0T52n3ganeqH-SOnv51MJpzf1BJ9k130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP477376.RA8UgOCxeQqHmN7v0T52n3ganeqH-SOnv51MJpzf1BJ9k130_provenance.
• NP1296605.RA5mNT0qhjIhv1CAsKeLTIu_omCDbrMh5UnnYOsWkDkuY130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1296605.RA5mNT0qhjIhv1CAsKeLTIu_omCDbrMh5UnnYOsWkDkuY130_provenance.